Globus Medical Inc. v. Jamison

CourtDistrict Court, E.D. Virginia
DecidedNovember 7, 2024
Docket2:22-cv-00282
StatusUnknown

This text of Globus Medical Inc. v. Jamison (Globus Medical Inc. v. Jamison) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Globus Medical Inc. v. Jamison, (E.D. Va. 2024).

Opinion

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Norfolk Division GLOBUSMEDICAL,INC, —~—*Sd Plaintiff, ) v. ) Case No. 2:22¢v282 SHANE JAMISON, et al., Defendants. □□ MEMORANDUM OPINION AND ORDER Before the Court is Defendants Shane Jamison, Mike Ruane, Mike Jones, Jake Schools, Scott Van Gilder, Sarah Gregory, Nick Walker, Curt McLeod, Terry McLeod, Scott Brooks, and Kurt Reighard’s (“Defendants,” collectively) Motion to Exclude the Expert Report and Testimony of Misty L. Decker (“Motion to Exclude”) and accompanying memorandum in support. ECF Nos. 192, 193. Therein, Defendants seek to exclude Plaintiff Globus Medical, Inc.’s (“Globus”) damages expert Misty L. Decker from testifying at trial pursuant to Federal Rule of Civil Procedure 7 and Federal Rule of Evidence 702. ECF No 192 at 1. The instant Motion argues that Decker’s report and testimony should be excluded because her “opinions have not been reliably applied to these facts because her analysis calculates damages sustained by the wrong entity; her analysis fails to attribute damages to individual defendants; and she fails to analyze lost sales where sales actually occurred.” Jd. at 2. Additionally, Defendants argue that “[b]ecause Decker fails to establish a causal link between the alleged harm to Plaintiff and Defendants’ actions, her report lacks a reliab[le] methodology and is not relevant.” Id. Globus filed a Memorandum in Opposition, ECF No. 220, and Defendants replied. ECF No. 222. The undersigned makes this ruling without a hearing pursuant to Federal Rule of Civil

Procedure 78(b) and Eastern District of Virginia Local Civil Rule 7(J). Accordingly, the matter is

now ripe for disposition. For the reasons explained below, Defendants’ Motion to Exclude is DENIED. I. FACTUAL AND PROCEDURAL BACKGROUND Globus filed its Third Amended Complaint against Defendants, Fusion Therapeutics, LLC, and Jonathan Walesczyk on December 18, 2023. ECF No 152. The Third Amended Complaint identifies Jamison, Ruane, Jones, Schools, Van Gilder, Gregory, Walker, Curt McLeod, Terry McLeod and Brooks as the “Sales Rep Defendants.” ECF No. 152 at 2. Each of the Sales Rep Defendants were formerly employed by Sky Surgical (“Sky”), a corporation that retained the exclusive rights to “market, sell, and distribute Globus’s spine surgery products” in a defined sales territory that spanned Southeastern Virginia through an “exclusive distributor agreement” (“EDA”) with Globus. ECF No. 152 at {J 1, 42. The Sales Rep Defendants signed non- competition, non-disclosure, and non-solicitation agreements (“NCNDAs”) before they began selling Globus products in the region. /d. at 13. Globus alleges that the Sales Rep Defendants coordinated with Reighard and others to breach these agreements and sell products manufactured by Globus’s competitors to doctors and hospitals in the territory where the Sales Rep Defendants previously sold Globus products. Jd. at ff] 1-19. Among other claims against additional defendants, Globus’s Third Amended Complaint alleges Breach of Contract against the Sales Rep Defendants, Unjust Enrichment (in the alternative) against the Sales Rep Defendants, Tortious Interference with Contractual Relationship against Curt McLeod, Terry McLeod, Scott Brooks, Mike Jones, Mike Ruane, Nick Walker, Sarah Gregory, Scott Van Gilder, Jake Schools, Shane Jamison, and Kurt Reighard, and Breach of Duty of Loyalty and Usurpation of Corporate Opportunities against Curt McLeod, Terry McLeod, Scott

Brooks, Mike Jones, Mike Ruane, Nick Walker, Sarah Gregory, Scott Van Gilder, Jake Schools, and Shane Jamison. ECF No. 152 at JJ 171-207. Globus retained Certified Public Accountant Misty L. Decker to opine on Globus’s damages related to the allegations in the Third Amended Complaint. ECF No 194 at 4. Globus asked Decker “to assume liability but express no opinions on such.” /d. at 4. Decker calculated Globus’s lost sales that Globus alleges resulted from Defendants’ wrongful conduct. Jd. at 13-14. Decker’s report quantifies Globus’s lost sales by facility. See, e.g., id. at 42 (calculating the Globus’s lost sales for the Chesapeake Regional Medical Center). Defendants filed the instant Motion to Exclude on October 3, 2024. ECF No. 192. Globus filed a Memorandum in Opposition on October 14, 2024. ECF No. 220. Defendants filed a reply on October 17, 2024. ECF No. 222. Il. LEGAL STANDARD Rule 26(a)(2)(B) of the Federal Rules of Civil Procedure provides in pertinent part that a retained expert must disclose “(i) a complete statement of all opinions the witness will express and the basis and reasons for them;” and “(ii) the facts or data considered by the witness in forming them.” Rule 702 of the Federal Rules of Evidence permits admission of “scientific, technical or other specialized knowledge” by a qualified expert if it will “help the trier of fact to understand the evidence or to determine a fact in issue,” “the testimony is based on sufficient facts or data,” “is the product of reliable principles and methods,” and “the expert’s opinion reflects a reliable application of the principles and methods to the facts of the case.” Fed. R. Evid. 702 (“Rule 702”); see also United States v. Wilson, 484 F.3d 267, 274—75 (4th Cir. 2007). The Court must ensure that an expert’s opinion is based on “knowledge and not on belief or speculation.” Sardis v.

Overhead Door Corp., 10 F.4th 268, 281 (4th Cir. 2021) (emphasis in original) (quoting Oglesby v. Gen. Motors Corp., 190 F.3d 244, 250 (4th Cir. 1999)). Expert testimony may be admitted pursuant to Rule 702 if the testimony is both relevant and reliable, considering a number of factors including whether the theory or technique “can be (and has been) tested,” whether it “has been subjected to peer review and publication,” whether it has been “generally accept(ed]” in the “relevant scientific community,” and “the known or potential rate of error.” Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 589, 593-94 (1993). ! The evaluation of these factors “can ‘depend[] on the nature of the issue, the expert’s particular expertise, and the subject of his testimony.” Sardis, 10 F.4th at 281 (quoting Kumho Tire Co. v. Carmichael, 526 U.S. 137, 150 (1999)). “Accordingly, trial courts are typically given ‘broad latitude’ to determine which of these factors (or some other unspecified factors) are ‘reasonable measures of reliability in a particular case.’” Jd. (citation omitted). Daubert’s relevance requirement “assures that the expert’s proposed testimony will ‘assist the trier of fact to understand the evidence or to determine a fact in issue’ as required by Fed. R. Evid. 702.” Garlinger v. Hardee’s Food Sys., Inc., 16 Fed. App’x. 232, 235 (4th Cir. 2001) (per curiam); Daubert 509 U.S. at 591 (“This condition goes primarily to relevance.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Kenneth Lehrman v. Gulf Oil Corporation
500 F.2d 659 (Fifth Circuit, 1974)
United States v. Paul Stanley
533 F. App'x 325 (Fourth Circuit, 2013)
Structural Polymer Group, Ltd. v. Zoltek Corp.
543 F.3d 987 (Eighth Circuit, 2008)
Sigur Ex Rel. Surplus Sales v. Emerson Process Management
492 F. Supp. 2d 565 (M.D. Louisiana, 2007)
Helpin v. Trustees of the University of Pennsylvania
10 A.3d 267 (Supreme Court of Pennsylvania, 2010)
R.F.M.A.S., Inc. v. So
748 F. Supp. 2d 244 (S.D. New York, 2010)
Oglesby v. General Motors Corp.
190 F.3d 244 (Fourth Circuit, 1999)
Brisbin v. Superior Valve Co.
398 F.3d 279 (Third Circuit, 2005)
Howard Nease v. Ford Motor Company
848 F.3d 219 (Fourth Circuit, 2017)
Fleur Bresler v. Wilmington Trust Company
855 F.3d 178 (Fourth Circuit, 2017)
Lipitor (Atorvastatin Calcium) Mktg. v. Pfizer, Inc.
892 F.3d 624 (Fourth Circuit, 2018)
Lance Belville v. Ford Motor Company
919 F.3d 224 (Fourth Circuit, 2019)
Rembrandt Social Media, LP v. Facebook, Inc.
22 F. Supp. 3d 585 (E.D. Virginia, 2013)
United States v. Wilson
484 F.3d 267 (Fourth Circuit, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
Globus Medical Inc. v. Jamison, Counsel Stack Legal Research, https://law.counselstack.com/opinion/globus-medical-inc-v-jamison-vaed-2024.